Skip to main content
Premium Trial:

Request an Annual Quote

Chemicon Sublicenses RNAi Technology from Promega

NEW YORK, Feb. 17 (GenomeWeb News) - Chemicon International has sub-licensed an RNAi technology from Promega, the companies said today.


Under the agreement, Temecula, Calif.-based Chemicon, a research division of Serologicals, has the right to develop and sell products for DNA-directed RNA interference for life science research. Promega will also help Chemicon develop ddRNAi products for studying mammalian genes.


Madison, Wis.-based Promega holds an exclusive license for ddRNAi technology from Benitec of Queensland, Australia.


The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.